This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously presented) An anti-IFN-α monoclonal antibody which binds to and neutralizes a biological activity of at least IFN-α subtypes IFN-α1, IFN-α2, IFN-α4, IFN-α5, IFN-α8, IFN-α10, and IFN-α21.

2. (Original) The antibody of claim 1 which is a murine antibody.

3. (Original) The antibody of claim 1 which is a humanized antibody.

4. (Original) The antibody of claim 1 which is a human antibody.

5. (Original) The antibody of claim 1 wherein said biological activity is antiviral activity.

6. (Original) The antibody of claim 5 wherein said antibody is capable of neutralizing at least 70% of the antiviral activity of said IFN-α subtypes.

7. (Original) The antibody of claim 5 wherein said antibody is capable of neutralizing at least 80% of the antiviral activity of said IFN-α subtypes.

8. (Original) The antibody of claim 5 wherein said antibody is capable of neutralizing at least 90% of the antiviral activity of said IFN-α subtypes.

9. (Original) The antibody of claim 5 wherein said antibody is capable of neutralizing at least 99% of the antiviral activity of said IFN-α subtypes.

10. (Cancelled)

11. (Previously presented) The antibody of claim 1 which is murine anti-human IFN-α monoclonal antibody 9F3 comprising an amino acid sequence of the monoclonal antibody produced by a hybridoma having ATCC Accession No. PTA-2917, or progeny thereof or a humanized or chimeric form thereof.

12. (Previously presented) The antibody of claim 11 which is humanized anti-human IFN-α monoclonal antibody comprising a light chain variable domain of SEQ ID NO:3 and a heavy chain variable domain of SEQ ID NO:5.

13. (Original) The antibody of claim 1 which binds essentially the same IFN-α epitope as the anti- IFN-α antibody produced by the hybridoma cell line deposited with ATCC on January 18, 2001 and having accession No. PTA-2917.

14. (Original) The antibody of claim 1 which is of the IgG class.

15. (Original) The antibody of claim 14 which has an IgG_1, IgG_2, IgG_3, or IgG_4 isotype.

16. (Original) The antibody of claim 1 which is an antibody fragment.

17. (Original) The antibody of claim 16 which is a Fab fragment.

18. (Original) The antibody of claim 16 which is a $F(ab')_2$ fragment.

19. (Original) The antibody of claim 16 which is a Fab' fragment.

20. (Currently amended) An ~~anti-IFN-α~~ antibody, or antigen binding fragment

thereof, comprising a heavy chain variable domain and a light chain variable domain, wherein the light chain variable domain comprises the following CDR's:

(a) L1 of the formula RASQSVSTSSYSYMH (SEQ ID NO: 7);

(b) L2 of the formula YASNLES (SEQ ID NO: 8); and

(c) L3 of the formula QHSWGIPRTF (SEQ ID NO: 9);

and wherein the antibody or antigen binding fragment specifically binds to at least IFN-α subtypes IFN-α1, IFN-α2, IFN-α4, IFN-α5, IFN-α8, IFN-α10, and IFN-α21.

21. (Currently amended) The ~~anti-IFN-α antibody~~ antigen binding fragment of claim 20 which ~~is~~ comprises a Fab.

22. (Currently amended) An ~~anti-IFN-α~~ antibody, or antigen binding fragment thereof, comprising a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises the following CDR's:

(a) H1 of the formula GYTFTEYJIIH (SEQ ID NO: 10);

(b) H2 of the formula SINPDYDITNYNQRFKG (SEQ ID NO: 11); and

(c) H3 of the formula WISDFFDY (SEQ ID NO: 12);

and wherein the antibody or antigen binding fragment specifically binds to at least IFN-α subtypes IFN-α1, IFN-α2, IFN-α4, IFN-α5, IFN-α8, IFN-α10, and IFN-α21.

23. (Currently amended) The ~~anti-IFN-α antibody~~ antigen binding fragment of claim 22 which ~~is~~ comprises a Fab.

24. (Previously presented) An anti-IFN-α antibody comprising

(A) at least one light chain or an antigen binding fragment thereof, comprising the following CDR's:

(a) L1 of the formula RASQSVSTSSYSYMH (SEQ ID NO: 7);

(b) L2 of the formula YASNLES (SEQ ID NO: 8); and

(c) L3 of the formula QHSWGIPRTF (SEQ ID NO: 9); and

(B) at least one heavy chain or an antigen binding fragment thereof, comprising the following CDR's:

(a) H1 of the formula GYTFTEYIIH (SEQ D NO: 10);

(b) H2 of the formula SINPDYDITNYNQRFKG (SEQ ID NO: 11); and

(c) H3 of the formula WISDFFDY (SEQ ID NO: 12).

25. (Original) The antibody of claim 24 having a homo-tetrameric structure composed of two disulfide-bonded antibody heavy chain-light chain pairs.

26. (Original) The antibody of claim 24 which is a linear antibody.

27. (Original) The antibody of claim 24 which is a murine antibody.

28. (Original) The antibody of claim 24 which is a chimeric antibody.

29. (Original) The antibody of claim 24 which is a humanized antibody.

30. (Original) The antibody of claim 24 which is a human antibody.

31-41. (Cancelled)

42. (Previously presented) A hybridoma cell line comprising a nucleic acid molecule encoding an antibody of claim 1.

43. (Original) A hybridoma cell line deposited with ATCC on January 18, 2001 and having accession No. PTA-2917.

44. (Original) An antibody produced by the hybridoma cell line of claim 42.

45. (Original) A pharmaceutical composition comprising an effective amount of the antibody of claim 1 in admixture with a pharmaceutically acceptable carrier.

46. (Original) A pharmaceutical composition comprising an effective amount of the antibody of claim 11 in admixture with a pharmaceutically acceptable carrier.

47. (Original) A pharmaceutical composition comprising an effective amount of the antibody of claim 12 in admixture with a pharmaceutically acceptable carrier.

48. (Original) A pharmaceutical composition comprising an effective amount of the antibody of claim 24 in admixture with a pharmaceutically acceptable carrier.

49.-54. (Cancelled)

55. (Currently amended) ~~An~~ The anti-IFN-α antibody of claim 1 which does not ~~bind to or~~ neutralize IFN-β.

56. (Currently amended) ~~An~~ The anti-IFN-α antibody of claim 1 which specifically binds to and neutralizes all IFN-α[[1]] subtypes.

57. (Previously presented) A cell line comprising a nucleic acid molecule encoding an antibody of claim 1.

58. (Previously presented) A cell line comprising a nucleic acid molecule encoding an antibody of claim 24.

59. (Previously presented) A cell line comprising a nucleic acid molecule encoding an antibody of claim 12.

60. (New) A pharmaceutical composition comprising an effective amount of the antibody of claim 20 in admixture with a pharmaceutically acceptable carrier.

61. (New) A pharmaceutical composition comprising an effective amount of the antibody of claim 22 in admixture with a pharmaceutically acceptable carrier.

62. (New) A cell line comprising a nucleic acid molecule encoding an antibody of claim 20.

63. (New) A cell line comprising a nucleic acid molecule encoding an antibody of claim 22.